Abstract: Natural Killer T (NKT) cells are unique lymphocytes characterized by their expression of a single invariant antigen receptor encoded by V,14J,18 in mice and V,24J,18 in humans, which recognizes glycolipid antigens in association with the monomorphic CD1d molecule. NKT cells mediate adjuvant activity to activate both CD8T cells to kill MHC-positive tumor cells and NK cells to eliminate MHC-negative tumor at the same time in patients, resulting in the complete eradication of tumors without relapse. Therefore, the NKT cell-targeted therapy can be applied to any type of tumor and also to anyone individual, regardless of HLA type.
1. Discovery of NKT cells expressing a unique single invariant V,14J, 18 antigen receptor in mice Natural killer T (NKT) cells were discovered as a unique lymphocyte lineage characterized by the expression of a single invariant T cell receptor (TCR) ,-chain encoded by V,14J,18 in mice and V,24J,18 in humans, which is predominantly associated with a limited repertoire of TCRO-chains, mainly VO8.2 in mice and VO11 in humans.
1)-3) The single invariant V,14J,18 receptor is exclusively used by NKT cells and, unexpectedly, not by conventional T cells even though both gene segments are present in a typical context within the TCR,-chain gene locus. These findings were unambiguously confirmed when it was shown that only NKT cells, but not conventional T cells or NK cells, developed when the invariant V,14J,18 together with TCRVO8.2 genes were introduced into RAG-knockout (KO) mice, 4) , 5) indicating that the rearrangement of V,14 and J,18 gene segments determines the commitment to NKT cell development.
In 1986, the discovery of murine invariant V,14J,18 NKT cell antigen receptor gene was made by evaluation of the TCR,-chain from 13 hybridomas with regulatory functions. 6 ), 7) Southern blot analysis of TCR,-chain gene usage by these 13 independently established hybridomas showed exactly the same DNA restriction fragment length polymorphism (RFLP) pattern, even after using three different enzymes, EcoRI, BamH I and HindIII. These results suggested the possibility that all the hybridomas used the same TCR,-chain, a result that would be contradictory to the central dogma, accepted even today, of the nearly unlimited diversity of TCRs and immunoglobulins. Therefore, we cloned the TCR,-chain cDNAs from these hybridomas and found that they could be classified into 4 types, all of which were, however, expressing the same V,14 and the same J,18 gene segments with only a one-nucleotide addition at the N-region being different in each clone, an C, A, T, or G nucleotide. Since this particular site of the N-region is in the third base of a glycine codon, any nucleotide addition at this position still encodes glycine, and thus the V,14J,18 antigen receptor is invariant at the amino acid level. 7) To exclude the possibility that our surprising results were due to an unknown bias in the hybridoma cloning, we carried out RNase protection assays in which C57BL/6 (B6) type 32 P-labelled antisense V,14J,18 mRNA derived from one of the hybridomas was hybridized with total mRNAs (sense) from normal B6 thymocytes. 8) In this assay, the samples are then treated with RNase to digest the unhybridized single stranded portion of the 32 P-labelled probe, thus "protecting" that portion of the probe that had hybridized with thymocyte mRNAs, leaving it intact (Fig. 1A) . Using this assay, we detected a single 630 bp protected 32 P-labelled antisense band in B6, a single 400 bp band in BALB/c, and 630/400 bp double bands of B6 and BALB/c types in DBA/2 mice (Fig. 1B) . Remarkably, the protected band(s) represented 2-4% of the total TCR, mRNA in the thymus of unmanipulated mice. The frequency of expression of any one particular TCR,-chain is theoretically estimated to be 1/10 6 , because there are 100 V, genes in the TCR, locus among a total repertoire of 10 8 TCR,-chains. 8) Therefore, the frequency of V,14J,18 expression that we detected in unmanipulated mice with different genetic backgrounds was more than 10 4 times higher than expected. This suggested that NKT cells were clonally expanded under physiological conditions without any external antigen stimulation.
We further sequenced V,14 genes from a total of 26 independent inbred laboratory mouse strains and classified into these 3 types according to the V,14 polymorphisms (B6 V,14 type: C57BL/10, B10(A), B10A (3R), B10A(4R), B10A(5R), C57Br; BALB/c V,14 type: A/J, AKR, A/WySn, CE/J, CDA/J, C3H, 129/J, I/LnJ, NZB, RIIIs/J, PL/J, WB/ReJ, RFM/MsNrs, SM/J SWM, SJL; DBA V,14 type: DBA/1, DBA/2), demonstrating that the V,14 gene is unique and very highly conserved in all laboratory The intensities of the bands circled in red were compared with the C, bands, which represent the total TCR, transcripts in the population. Adopted from our original paper. 8) NKT cell-targeted anti-cancer adjuvant cell therapy No. 7] mouse strains.
9) The above mentioned paper on the discovery of invariant NKT cells published in 1990 was selected by The American Association of Immunologists as one of the "The Pillars of Immunology" for its enormous impact on the field.
10)
Based on the above results, we concluded that the expression of V,14J,18 in mice and V,24J,18 in humans is a defining signature of NKT cells that clearly distinguishes them from conventional T cells. Other differences between NKT and conventional T cells have since been recognized; NKT cells belong to either DN or CD4 D populations, express CD69, CD5
high , CD44 and NK1.1, are present in the thymus, liver, spleen and BM, and produce both Th1 and Th2 cytokines.
11)-15) Moreover, NKT precursor cells express the granulocyte macrophage colony stimulating factor receptor (GM-CSFR) and undergo V,14 gene rearrangement after receiving GM-CSF signals. 16) More surprisingly, the circular DNA created by the V,14 and J,18 gene rearrangement event was detected at an early stage in embryogenesis. 9) All of these mammalian species possessed "V,14" genes similar but not identical to V,14 subfamilies in B6, BALB/c and DBA laboratory strains. Most nucleotide substitutions in these "V,14" genes were found at the first and the second nucleotide positions of codons, suggesting a higher frequency of non-synonymous nucleotide mutations in the "V,14" sequences in the different species. As shown in Table 1 , at the time of species divergence the frequencies of non-synonymous mutations were higher than those of synonymous mutations (Apodemus vs. M. musculus or other Mus species, and Rattus vs. Hamster). In fact, the ratio of non-synonymous vs synonymous substitutions was more than 1.0 when "V,14" genes in Apodemus were compared with those in M. musculus or Mus species. In general, amino acid substitutions in most conventional TCR V regions other than V,14 gene (e.g., V,1) are neutral during evolution as suggested by the theory proposed by Kimura. 18) In fact, the ratio of non-synonymous vs synonymous nucleotide substitutions in conventional T cell ,O receptor V region genes is generally 0.58 at the first, 0.47 at the second and 0.89 at the third nucleotide positions, respectively, as reported by Lu and Nei. 19) Therefore, these observations suggest that positive selection of the "V,14" genes occurred at the time of the divergence of Apodemus to M. musculus or Mus species (Table 1) . Similarly, higher non-synonymous/synonymous ratios were observed at the species divergence between Hamster and Rattus (0.953), supporting the idea that positive Darwinian selection is operating in the different species. These results suggest that the "V,14" gene family, unlike the conventional TCRV, genes, is selectively affected by environmental factors, indicating that NKT cells bearing "V,14" antigen receptors are essential for the survival of species as they adapt to environmental changes during evolution.
Identification of ,-galactosylceramide
as an NKT cell ligand
For several years, the identity of NKT cell ligand(s) was an enigma. Then, in 1997, we discovered a ligand for NKT cells as a glycolipid, ,-galactosylceramide (,-GalCer), which is presented by the monomorphic MHC class I-like CD1d molecule. 5) The idea that an NKT cell ligand might be a glycolipid was suggested by experiments using mice lacking the transporter associated with antigen processing (TAP-KO). 20) TAP is essential for translocation of cytoplasmic peptides into the endoplasmic reticulum where they form a stable complex with nascent MHC class I molecules. Since CD8T cells require the MHC-peptide complex for their selection and proliferation, MHC class I-restricted CD8T cells were not generated in TAP-KO mice. Interestingly, however, when using the invariant V,14J,18 probe in RNase protection assays we could detect significant levels of protected bands in TAP-KO as well as MHC class II-KO mice but not in O2M-KO mice. 20) These results strongly suggested that the NKT cell ligand was definitely not a peptide, but likely to be a glycolipid, lipid or carbohydrate that associated with a O2M-associated MHC class I-like molecule.
At the time of the discovery of ,-GalCer as the NKT cell ligand, 5) the relevant MHC class I-like molecule was discovered to be the non-polymorphic CD1d, which has two large hydrophobic AB and FB pockets potentially allowing it to accommodate lipids with a carbon (C):25 chain length in the AB and a C:20 chain length in the FB pockets. 21 ) Thus, we speculated that an NKT cell ligand should have both hydrophilic and hydrophobic properties, because of its requirement for binding with both hydrophobic CD1d pockets and the hydrophilic V,14 antigen receptor. Based on these parameters, we identified ,-GalCer with C:25 fatty acyl chain and C:18 sphingosine as an NKT cell ligand by screening various synthetic glycolipids 5) and determined the important positions critical for the recognition by NKT cells based on the structure-function relationships ( Fig. 2A) , such as 1) ,-linkage but not Olinkage between the carbohydrate moiety and the ceramide portion of the glycolipid, 2) a 3-OH on the sphingosine of the ceramide, 3) a 2-OH configuration on the sugar moiety on the glycolipid, e.g., ,-GalCer or ,-GluCer, different from ,-ManCer. 5) In addition, by functional assays using mutant CD1d molecules with alanine substitutions, we also identified important CD1d amino acid residues, such as Arg79, Asp80, Glu83, and Gln153, for activation of NKT cells in the mouse system. 22) 4. CD1d amino acids important for binding ,-GalCer and/or the invariant human V,24 NKT cell receptor
In 2007, Borg et al. succeeded in crystallizing the triple complex of ,-GalCer/human V,24J,18 with TCRVO11/human CD1d. 23) Interestingly, only the V,24J,18 chain docks in parallel with the cleft created by the two ,-helices of the CD1d molecule for both ligand-and CD1d-binding, without any direct contribution of the TCRO-chain (Fig. 2B) . The TCRO-chain, however, binds with the external portion of the CD1d molecule to support V,24J,18-mediated antigen binding. When compared to ligand recognition by conventional T cells this situation is quite unusual because, in general, the antigen peptide presented loaded on MHC molecule is recognized by the TCR,O-chain, not by only the TCR,-chain itself. 24) The structure also revealed that the first 4 amino acids (Asp94, Arg95, Gly96 and Ser97) of J,18, which are conserved in mouse and human (Fig. 2C) , are essential for binding with both CD1d and ,-GalCer (Fig. 2B) . The Asp94 in J,18 binds with Arg79 of CD1d, Arg95 in J,18 with Arg79/ Ser76/Asp80 of CD1d and the 3-OH on the sphingosine, Gly96 in J,18 with the 2-OH on the galactose, and Ser97 in J,18 with Gln150 of CD1d (Fig. 2B) . Interestingly, the Glu83 of CD1d, although it makes no direct contribution to binding the ligand, is important for binding with the TCROchain to make a stable complex with CD1d. Moreover, the CD1d amino acids Ser76, Arg79 and Asp80 (Fig. 2B) , which are responsible for binding with either ,-GalCer or J,18, are also conserved among species.
25)-27) In fact, ,-GalCer was first identified as a murine NKT cell ligand, but was subsequently shown to activate human NKT cells and thus can be used for human studies.
NKT cell-mediated adjuvant activities augment anti-tumor immune responses
For the development of anti-cancer immunotherapy, the following three issues have to generally be considered. The first is that, for an optimal therapy, both MHC-positive and -negative tumor cells should be eliminated simultaneously to avoid tumor relapse, because tumors in general contain both cell types. The second important point is that tumor cells do not usually contain any endogenous adjuvant materials because, unlike pathogens, they are derived from autologous cells, so that it is difficult to mount efficient anti-tumor immune responses in patients without adjuvant. The third point is that it is essential to convert DCs from an immature to mature state in the tumor patients to induce efficient protective responses, because most advanced cancer patients are immune deficient.
Activation of NKT cells with ,-GalCer promotes production of IFN., which induces NKT cellmediated adjuvant activity, activating both NK and CD8T cells and bridging innate and acquired immune systems 28) and thus overcoming the problem of the tumor-relapse because it induces clonal expansion of antigen-specific CD8T cells and activation of NK cells as well as maturation of immature DCs in patients (Fig. 3A) . 29),30) Therefore, NKT celltargeted therapy should be useful for treatment of advanced cancer patients, whose specific CD8T cells, even though they are present in patients, fail to expand, because DCs are usually immature due to the immune suppressive cytokines, such as interleukin (IL)-10 or TGFO, produced by tumor cells. 31) Unlike other lymphocytes, only NKT cells have the ability to interact with immature DCs in the presence of ,-GalCer, leading to the induction of full maturation of DCs through CD40-CD40L interactions, 32) , 33) resulting in their robust production of IL-12 to further activate NKT cell production of IFN-.. The end result of these cellular interactions is the activation of both CD8 cytotoxic T cells and NK cells to eliminate MHC-positive and -negative tumor cells, respectively, resulting in tumor eradication without relapse (Fig. 3A) . In fact, it was experimentally demonstrated the strong adjuvant activity mediated by NKT cells is observed in a tumor model using OVA as an artificial tumor antigen 30),32) (Fig. 3B) . In this experiment, mice were immunized with OVA-loaded TAP-KO spleen cells together with ,-GalCer; TAP-KO mice were used because they are unable to present peptide antigen to conventional CD8T cells. For the detection of IFN-. production, we stimulated spleen cells with OVA peptide in vitro and observed significant production of IFN-. by NK cells and CD8T cells (Fig. 3C) , as well as a robust increase in the number of OVA-specific IFN-. producing CD8T cells in vivo (Fig. 3D) and, importantly, suppression of the OVAexpressing EL4 (EG7) tumor growth (Fig. 3E) . A) The structure of ,-GalCer. The ,-linkage between carbohydrate and ceramide portions, the 2-OH on the galactose and the 3-OH on the sphingosine are important for the binding with J,18 and CD1d (see 2B). B) Schematic diagram of the crystal structure of triple complex of human V,24J,18/VO11, ,-GalCer and human CD1d. The first 4 amino acids of J,18 in the CDR3 region (see 2C) in yellow circles interact with CD1d amino acids in red circles as well as with the 2-OH on the galactose and 3-OH on the sphingosine. These interactions were also detected by a functional assay with alanine substitution of CD1d. 22) Glu83 on CD1d is the binding site for the TCRVO chain. The importance of Ser76 on CD1d could not find by the functional assays. C) The conserved CDR3 region of the invariant NKT cell antigen receptor in mouse and human. In particular, the first four amino acids (DRGS) in J,18 in mouse and human are responsible for binding both ,-GalCer and CD1d (see 2B).
Therefore, NKT cell-targeted anti-tumor immunotherapy overcomes the major problem of tumor relapse usually observed with current anti-cancer immunotherapies, which target only one type of antitumor immune effector cells. For example, in the immunotherapy using tumor antigen peptides or antibodies against PD-1 or CTLA4, the target is a CD8T cell, which kills MHC-positive but not -negative tumor cells, resulting in the recurrence of an MHC-negative tumor. Similarly, in the artificial cells recently developed by the forced expression of NK receptor ligands, such as Rae1/H60/Mult-1 (NKG2D-L), or TNF ligand (CD70-L), the target cell is an NK cell, which eliminates only MHC-negative tumor cells, resulting in relapse with MHC-positive tumor cells. Only NKT cells, and not other effector cell types, simultaneously activate both CD8T and NK cells, resulting in the simultaneous elimination of both MHC-positive and -negative tumor cells. Therefore, NKT cell-targeted therapy is a promising treatment option for tumor treatment to overcome tumor relapse.
Clinical trials of NKT cell-targeted therapy in cancer patients
We carried out preclinical studies using the liver metastasis model of the murine B16 melanoma to investigate the clinical efficacy of NKT cell-targeted therapy using ,-GalCer-DCs. Mice bearing metastatic melanoma nodules 1-2 mm in diameter in the liver were treated by intravenous administration of ,-GalCer-DCs; this therapy resulted in the complete eradication of melanoma metastasis within 7 days.
34)
Based on the dramatic effects of ,-GalCer-DCs in the mouse melanoma model, we conducted clinical trials to evaluate clinical outcomes: 1) at Chiba University hospital, in collaboration with Profs. T. Nakayama and S. Motohashi, of NKT cell-targeted therapy using ,-GalCer-DCs on patients with advanced lung cancer, and 2) with Prof. Y. Okamoto in patients with head and neck tumors (Fig. 4) . No severe adverse events related to the NKT celltargeted therapy were observed in the Phase I clinical trials. 35) , 36) We then carried out Phase II clinical trials on 17 cases with advanced (IIIB, IV) or recurrent non-small cell lung cancer refractory to the standard treatments, including surgery, chemotherapy and radiation therapy. The patient's peripheral blood mononuclear cells (PBMCs), which were cultured with GMP-grade GM-CSF and IL-2 and pulsed with ,-GalCer (,-GalCer-DCs), were administered intravenously into autologous patients (1.6 # 10 9 cells/m 2 ).
37),38)
Since IFN-. produced by NKT cells serves as an adjuvant and thus could be a functional marker for patient NKT cells, we investigated the relationship between the ability of the patient PBMCs to produce IFN-. and the clinical efficacy of the therapy. A dramatic increase (25-60 fold) in the number of IFN-.-producing PBMCs assayed by ELISPOT was observed in 10 out of 17 (60%) patients. 38 ) These 60% of patient group with high IFN-. production had a significantly prolonged median survival time (MST, 29.6 Mo) (Fig. 4A) . Because of the clinical correlation between the increased number of IFN-.-producing NKT cells in the tumor in situ as well as PBMCs with prolonged overall survival, IFN-. could be a good marker for predicting the clinical efficacy of this treatment. 38 ),39) Although we cannot directly compare the clinical outcomes of all patient groups due to the different protocols and hospitals, the overall median survival time (18.6 Mo) of total 17 patients completed with the NKT cell-targeted therapy was superior to that of patients treated with other types of therapies, such as molecular target drug treatment (average about 10 Mo) 40)-43) (Fig. 4A) .
In the case of the head and neck tumors, we used a combination therapy of sub-mucosal injection of ,-GalCer-DCs (10 8 ) near the tumor and the activated NKT cells (5 # 10 7 ), which were infused into the regional artery of the tumor. 44) Ten patients, who had advanced or recurrent disease after standard chemotherapy, including patients with pharyngeal, laryngeal, esophageal, maxillary, and oral carcinomas, completed the trial. All 10 cases had either a partial response (PR) or achieved a stable disease status (SD), indicating a significant clinical efficacy (Fig. 4B) , which was associated with signifi- cant NKT cell infiltration into the tumor in situ, similar to that observed in cases of advanced lung cancer. 38), 44) In the cases with PR, we observed a decrease in tumor size and necrosis at the center of the tumor.
Currently, we are conducting randomized Phase II clinical trials in collaboration with National Hospital Organizations (Drs. Ito, S., Saka, H. and Ichinose, Y.) using ,-GalCer-DCs for treatment of stage IIA-IIIA non-small cell lung cancer patients after radical surgery. We have chosen this patient population because 70-75% of them will experience relapse after surgical resection of the primary tumor.
Because of its significant effects on various tumor cell types, the NKT cell-targeted adjuvant cell therapy was approved by the Japanese government for the advanced medical care assessment system (B) on advanced non-small cell lung cancer in 2011, head and neck tumors in 2013, and Stage IIA-IIIA non-small cell lung cancer after surgery in 2014. Since the clinical efficacy was not formally confirmed by the two-arm study, it is now being evaluated in the current clinical trials using the advanced medical care assessment system.
Generation of iPS cells from mature NKT cells
The clinical efficacy of NKT cell-targeted therapy looks promising, however, in the case of advanced cancer patients, two thirds of them are not eligible for this therapy due to their cancer-mediated immunodeficiency, which results in a limited number of NKT cells. It is also difficult to obtain enough NKT cells for clinical use with the current in vitro culture system. To overcome these problems, we established in vitro methods for the generation of unlimited numbers of functional NKT cells by using iPS technology. 45) Such in vitro generated cells could then be transferred into the advanced cancer patients who have few of their own NKT cells.
In our previous studies using mouse embryonic stem (ES) cells, we replaced the ES cell nucleus with a nucleus derived from a mature NKT cell (NKT cloned ES) by nuclear transfer. Using this approach, we have successfully generated a large number of NKT cells in vitro, which could mediate adjuvant activity in vivo and regress tumor growth.
46) The efficiency of reprogramming of lymphocytes by using iPS technology with Klf4, Sox2, Oct3/4 and c-Myc genes was originally reported to be very low. 47) However, based on the frequency of establishing ES cells by nuclear transfer into enucleated unfertilized eggs, we discovered that NKT cells have a higher reprogramming efficiency (71%) compared to conventional T cells (12%). 46 ) Therefore, we speculated that NKT cells would be suitable for reprograming and generating iPS cells.
In fact, we efficiently generated iPS cells from mature NKT cells. 48) Isolated mature B6 NKT cells (10 6 ) were first stimulated with CD3/CD28 mAb and then cultured with IL-12/IL-2 for 7 days, followed by reprogramming according to the conventional protocol using Klf4, Sox2, Oct3/4 and c-Myc genes. We have established several iPS cell lines harboring a rearranged NKT cell-derived V,14J,18 gene. In terms of gene expression profiles, we found that iPS cells established in this way are similar to ES cells but different from fibroblasts in terms of their expression of endogenous Klf4, Sox2, Oct3/4, Nanog, Rex1, Ecat1, Zfp296, and Gdf3 mRNA as well as in genomewide gene expression profiles. Moreover, Oct3/4 and Nanog genes are demethylated in NKT cellderived iPS cells, similar to ES cells, while those are methylated in fibroblasts.
Development of functional NKT cells from iPS cells
The ability of the iPS cell lines to develop into functional NKT cells was investigated in a culture system using OP9/Dll-1 stromal cells in the presence of IL-7 and Flt-3L for 25 days. 48) Using this culture system, we obtained 3 # 10 7 NKT cells, a 300-fold expansion, from 10 5 iPS cells. Upon either CD3/ CD28 mAb or ,-GalCer-DC stimulation, the NKT cells generated in vitro produced significant amounts of IFN-., essential for their adjuvant effect in antitumor responses, indicating that the iPS-derived NKT cells represent functional NKT cells. It is worthwhile mentioning that the NKT-derived iPS cells preferentially generated NKT cells and also a small number of CD11b D macrophages, but not ./T, ,OT, NK or B cells in the in vitro 25 day-culture system. 48) Moreover, iPS cells derived from fibroblasts failed to generate NKT cells under the same culture conditions, most likely because the frequency of the successful rearrangement of the required V,14 and J,18 combination is estimated to be very low, less than 1/10 8 . Therefore, the pre-rearranged V,14 gene in the natural chromosomal context predisposes the NKT cell fate.
In vivo function of iPS-derived NKT cells
The in vivo function of iPS-derived NKT cells was investigated by transfer into NKT-KO mice (Fig. 5) . 48) A considerable number of iPS-derived NKT cells were detected in vivo, even 6 weeks after cell transfer. The transferred iPS-derived NKT cells produced large amounts of INF-. upon intravenous administration of ,-GalCer-DCs and expanded significantly in number. Moreover, we observed expansion of NK cells and their production of INF-. as the result of NKT cell-mediated bystander adjuvant activity.
To investigate the adjuvant activity on the acquired immune system mediated by iPS-derived NKT cells, we again used the OVA model as an artificial tumor antigen. 48) NKT-KO mice that had received iPS-derived NKT cells were immunized with OVA-pulsed spleen cells followed by stimulation with ,-GalCer. We observed a 48-fold increase in the number of OVA-specific IFN-. producing CD8T cells, similar to that seen (51 fold) in WT mice (Fig. 5A) . Under these conditions, we obtained significant growth suppression of the OVA-expressing EL4 (EG7) tumor (Fig. 5B) .
Since NKT cells are highly conserved between mice and humans in terms of their function and ,-GalCer reactivity, we confidently expect that it will be possible to expand functional human NKT cells from human-iPS cells in vitro and to use the iPSderived functional human NKT cells in the clinical setting.
Future directions for NKT cell-targeted therapy using iPS-derived NKT cells
Two immunological issues need to be addressed before clinical application of iPS-derived NKT cells: one is whether NKT cells induce GvHD, because various cell types, including conventional CD4T cells, are reported to induce GvHD, and the other is whether semi-allogeneic NKT cells will be functional in vivo, because semi-allogeneic iPS-derived NKT cells will be rejected by the patients soon after the cell transfer.
Related to the first question, allogeneic B6 NKT cells as well as syngeneic BALB/c CD4T cells as a control did not induce GvHD, whereas allogeneic B6 CD4T cells induced a fulminant GvHD characterized by weight loss, diarrhea, skin disease, or death when injected into BALB/c RAG-KO mice (Fig. 6A) .
Concerning the second issue on the in vivo effects of semi-allogeneic NKT cells, we transferred (129 # B6) F1 NKT cells derived from cloned NKT-ES cells into B6 NKT-KO mice followed by immunization with ,-GalCer in the OVA artificial tumor antigen model as described above (see Fig. 3B ). A significant increase in the number of IFN-.-producing OVA-specific CD8T cells (Fig. 6B ) and the significant suppression of OVA-bearing tumor (EG7) growth (Fig. 6C ) was detected. Since the transferred semi-allogeneic F1 NKT cells will be eliminated in a few days, this strategy reduces the intrinsic anxiety on tumorigenicity of iPS-derived cells in vivo. The use of in vitro-generated NKT cells derived from iPS cells, therefore, offers a powerful option for the establishment of optimal NKT celltargeted therapy. In 2013, the projects on the clinical application of human iPS-derived NKT 
